- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07846787
Control of Myopia in Young Children Using H.O.P.E. Lenses Combined With 0.02% Atropine Eye Drops
A Multicenter, Prospective, Intervention Study on the Control of Myopia in Young Children Using High-order Phase Element Array Microstructure Lenses (H.O.P.E.) in Combination With Low-concentration Atropine Eye Drops (0.02%)
A multicenter, prospective, intervention study on the control of myopia in young children using high-order phase element array microstructure lenses (H.O.P.E.) in combination with low-concentration atropine eye drops (0.02%)
Aperçu de l'étude
Statut
Les conditions
Description détaillée
This study focused on 6-9-year-old young children as the research subjects, aiming to investigate 1. The effectiveness of using H.O.P.E. lenses alone and in combination with 0.02% atropine eye drops, in order to provide data support and clinical guidance for the clinical effectiveness and safety of the high-order phase unit (H.O.P.E.) array microstructure lenses in young children with myopia.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Meinan He
- Numéro de téléphone: 13672135765
- E-mail: hmn509@tmu.edu.cn
Lieux d'étude
-
-
-
Tianjin, Chine
- Tianjin Medical University Eye Hospital
-
Contact:
- Meinan He
- Numéro de téléphone: 13672135765
- E-mail: hmn509@tmu.edu.cn
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age: 6-9 years old (6 years old but under 10 years old), gender not restricted;
- Clinically diagnosed with bilateral myopia (after cycloplegia), refractive error within -6.00D < SER ≤ -0.50D, astigmatism ≤ 1.50D, refractive anisometropia ≤ 1.50D (based on subjective refraction values);
- Corrected visual acuity LogMAR ≤ 0.1;
- Able to understand the research purpose, voluntarily participate, and the subject and his/her legal guardian sign the informed consent form.
Exclusion Criteria:
If a subject meets any of the following exclusion criteria, they will not be included in this study:
- Those who have discontinued the use of atropine eye drops (due to glaucoma or a tendency towards glaucoma, or are allergic to scopolamine or the components of this product);
- Those currently suffering from any of the following diseases that may affect vision or refractive errors, or ocular organic diseases: such as diseases causing damage to the lens like cataracts, glaucoma, macular degeneration, corneal diseases, uveitis, retinal detachment, severe vitreous opacity, acute/chronic keratitis, conjunctivitis, irregular cornea, keratoconus, manifest strabismus, fundus diseases, etc.; systemic diseases that may affect the eyes, such as immune system diseases, central nervous system diseases, Down syndrome, asthma, epilepsy, severe heart or lung function disorders, severe liver or kidney function impairments, etc.;
- Those who have participated in other clinical trials or studies related to myopia control within 90 days before signing the informed consent form;
- Those who have used myopia control products within 90 days before signing the informed consent form (such as near-axial lenses, low-concentration atropine eye drops, corneal reshaping lenses, red light, etc.);
- Those who cannot wear glasses regularly or use the medication as required (such as having a significant difference in compliance);
- During the screening period, the intraocular pressure of either eye is greater than 21 mmHg or less than 10 mmHg, or the intraocular pressure difference between both eyes is ≥ 5 mmHg;
- There is a severe abnormality in the accommodative function (accommodative amplitude < 8D);
- Only one eye meets the inclusion criteria;
- Other situations that the researcher deems unsuitable for participating in this study.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Group A (H.O.P.E. Lens Group)
Wearing H.O.P.E. lens frame glasses (provided by Shenyang Kangnd Medical Technology Co., Ltd.) |
Wear the H.O.P.E. lens frame glasses and use the placebo. Use it once per night for both eyes. |
|
Comparateur actif: Group B (0.02% Atropine group)
Use 0.02% atropine sulfate eye drops (provided by Shenyang Xingqi Eye Pharmaceuticals Co., Ltd.) |
Wear single-vision frame glasses and use 0.02% atropine sulfate eye drops twice a day, once at night for both eyes. |
|
Expérimental: Group C (H.O.P.E. lenses + 0.02% atropine group)
Wearing H.O.P.E. lens frame glasses (provided by Shenyang Kangnd Medical Technology Co., Ltd.); Use 0.02% atropine sulfate eye drops (provided by Shenyang Xingqi Eye Pharmaceuticals Co., Ltd.) |
Wear the H.O.P.E. lens frame glasses and use the placebo. Use it once per night for both eyes. Wear single-vision frame glasses and use 0.02% atropine sulfate eye drops twice a day, once at night for both eyes. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
The final spherical equivalent refractive error (SER) measured by cycloplegic refraction combined with both automated and subjective refraction after 12 months of wearing glasses, compared with the baseline value.
Délai: From enrollment to the end of treatment at 12 months
|
From enrollment to the end of treatment at 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
The change in AL (axial length) from the baseline after wearing the glasses for 12 months
Délai: From enrollment to the end of treatment at 12 months
|
From enrollment to the end of treatment at 12 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Ruihua Wei, Tianjin Medical University Eye Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- KCAK260A2026001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .